Tempus extends BMS AI oncology pact to 2031

Tempus AI has expanded its multiyear oncology data licensing agreement with Bristol Myers Squibb, extending the collaboration through December 31, 2031. Under the deal, Bristol Myers Squibb becomes one of Tempus’s largest licensees of de-identified oncology data, reinforcing an established strategic relationship focused on applying artificial intelligence and multimodal real-world data to oncology and neuroscience programs.

The oncology agreement provides Bristol Myers Squibb with increased access to Tempus’s de-identified oncology dataset and related analytic services, supporting drug discovery and therapeutic development. Tempus will license certain oncology records, grant access to its Lens software for data analysis, and deliver additional research services over the course of the agreement.

Tempus has entered data licensing agreements with Bristol Myers Squibb and Pathos AI that are expected to provide aggregate cash payments of up to $192.5 million over approximately five years. Within this framework, Bristol Myers Squibb will make fixed payments totaling $137.5 million for the oncology data license, Lens access, and associated services, with invoices issued on a quarterly schedule during the term of the agreement, which expires at the end of 2031.

The arrangements are documented through a Statement of Work between Tempus and Bristol Myers Squibb covering oncology data and services, an Order Form between Tempus and Pathos for neurology data and an agentic data analysis tool, and a side letter among Tempus, Pathos, and Bristol Myers Squibb addressing sublicensing and exclusivity. The side letter confirms Tempus’s consent for Pathos to sublicense certain data and tools to Bristol Myers Squibb and limits Tempus from licensing specified neurology records to other parties for a defined period.

As part of the expanded collaboration, Bristol Myers Squibb will gain access to Tempus’s Lens Platform, described as an AI-first, agentic environment for oncology drug development built on a large, real-world multimodal dataset. The platform is connected to state-of-the-art GPU infrastructure, enabling Bristol Myers Squibb researchers to train and execute advanced AI models using de-identified clinical and molecular data.

This dedicated environment is intended to support the identification of potential breakthroughs more rapidly and to increase the probability of technical success when developing candidate therapies at scale. It builds on prior work between the companies that has used AI and multimodal real-world data to optimize clinical trial design across high-priority oncology and neuroscience initiatives.

In addition to the oncology-focused collaboration, Tempus will license neurology data to Pathos AI for use in Pathos’s collaboration with Bristol Myers Squibb. The agreements allow Bristol Myers Squibb to use Tempus’s oncology data in combination with Pathos’s Foundry drug development platform, integrating de-identified datasets, analytic tools, and AI capabilities.

The restrictions on neurology data licensing and the sublicensing provisions are designed to govern how Pathos and Bristol Myers Squibb can access and use Tempus’s data and tools over the agreement period. Together, the oncology and neurology arrangements extend and broaden the scope of Tempus’s long-standing strategic relationship with Bristol Myers Squibb in data-driven drug development.

Tempus positions itself as a technology company focused on advancing precision medicine through the practical application of artificial intelligence in healthcare. It maintains one of the world’s largest libraries of multimodal data and an operating system that makes these data accessible for AI-enabled precision medicine solutions.

Through collaborations such as the expanded Bristol Myers Squibb partnership and the related Pathos AI agreements, Tempus seeks to facilitate the discovery, development, and delivery of therapeutics while providing tools that help physicians tailor treatment. The company’s objective is to enable each patient to benefit from insights derived from prior patients as its datasets and AI models continue to grow.